The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Monitoring for and managing CLS in patients with BPDCN treated with tagraxofusp-based regimens
In this video, Andrew Lane, MD, PhD, Dana Farber Cancer Institute, Boston, MA, briefly discusses capillary leak syndrome (CLS), a toxicity associated with tagraxofusp-based regimens in blastic plasmacytoid dendritic cell neoplasm (BPDCN). Dr Lane emphasizes the importance of awareness and close monitoring of patients, particularly during the first cycle of therapy. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So the most important toxicity to think about with tagraxofusp is capillary leak syndrome, or CLS. This is kind of unique compared to other chemotherapy drugs. So the most important thing is awareness. So patients need to be closely monitored, especially during the first cycle. Every day we need to monitor their weight, albumin, and other vital signs to make sure they’re not developing CLS...
So the most important toxicity to think about with tagraxofusp is capillary leak syndrome, or CLS. This is kind of unique compared to other chemotherapy drugs. So the most important thing is awareness. So patients need to be closely monitored, especially during the first cycle. Every day we need to monitor their weight, albumin, and other vital signs to make sure they’re not developing CLS. And at any sign of CLS, you hold the drug and you treat with, as appropriate, diuretics, fluid replacement, sometimes even steroids. This is not as big of an issue in second cycle and beyond, which is why second cycle and beyond can be given as an outpatient safely.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
